


 MANUAL OF PATENT EXAMINING PROCEDURE
 PTO/SB/08 (2-92)

Sheet 1 of 6

Form PTO-1449

 INFORMATION DISCLOSURE CITATION
 IN AN APPLICATION

(Use several sheets if necessary)

 Docket Number (Optional)
 3115.00017

 Application Number
 10/015123

 Applicant
 John Hadden

 Filing Date
 10/26/01

 Group Art Unit
 1633

 RECEIVED
 JUN 13 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
h3L	4,036,953	07/19/77	Adam et al.			11/17/72
	4,116,951,	09/26/78	Wang			01/23/78
	4,353,821	10/12/82	Birr et al.			03/24/80
	4,390,623	06/28/83	Frabricius et al.			03/26/81
	4,439,196	03/27/84	Higuchi			03/18/82
	4,447,224	05/08/84	DeCant, Jr. et al.			09/20/82
	4,447,233	05/08/84	Mayfield			07/30/82
	4,454,355	06/12/84	Schubert et al.			05/24/82
	4,466,918	08/21/84	Birr et al.			07/29/82
	4,470,926	09/11/84	Birr et al.			03/25/80
	4,475,196	10/02/84	LaZor			03/06/81
	4,486,194	12/04/84	Ferrara			06/08/83
	4,487,603	12/11/84	Harris			11/26/82
	4,612,365	09/16/86	Birr et al.			04/02/84
	4,910,296	03/20/90	Birr et al.			06/26/86
	4,925,678	05/15/90	Ranney			04/01/87
	4,959,217	09/25/90	Sanders et al.			05/22/86
	5,100,664	03/31/92	Doyle et al.			06/30/89
	5,167,616	12/01/92	Haak et al.			12/14/89
	5,169,383	12/08/92	Gyory et al.			
	5,225,182	07/06/93	Sharma			10/31/91

O I P E
JUN 1 1 2002
RECEIVED
JUN 1 3 2002
TECH CENTER 1600/2900

✓	5,376,369	12/22/94	Allison et al.		02/08/90
	5,503,841	04/02/96	et al.		02/24/89
	5,632,983	05/27/97	Hadden		11/17/94
	5,643,565	07/01/97	Doyle et al.		09/09/95
	5,679,356	10/21/97	Bonnem et al.		07/07/93
	5,698,194	12/16/97	Hadden		02/29/96
	5,747,024	05/05/98	Grabstein et al.		07/19/95
	5,800,810	09/01/98	Doyle et al.		10/17/96
	5,849,307	12/15/98	Metz et al.		03/26/97
	6,017,537	01/25/00	Alexander et al.		12/18/98
✓	6,060,068	05/09/00	Doyle et al.		08/31/98

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

✓	Albert et al, "letter to nature", Nature, Vol. 392, pp.86-89, 1998.
	Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. "Combination immunotherapy of squamous cell head and neck cancer: A phase II trial", Arch Otolaryngol Head Neck Surg 126:345-351, 2000.
	Bellone et al. "Cancer immunotherapy: synthetic and natural peptides in the balance", Immunology Today, Vol 20, No. 10, p 457-462, 1999
	Berd D, Mastrangelo MJ. "Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T suppressor function without depletion of the CD8+subset", Cancer Research 47:3317-3321, 1987.
	Berd D. "Low doses of chemotherapy to inhibit suppressor T cells", Progress in Clin Biol Res 288:449-458, 1989.
	Borysiewicz LK, Fiander A, Nimako M., Man, S., Wilkinson, GW., Westmoreland, D., Evans, AS., Adams, M., Stacey, SN., Boursnell, ME., Rutherford, E., Hickling, JK., Inglis, SC. "A recombinant vaccine virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer", Lancet 347: 1524-1527, 1996.
	Burke and Olson, Methods in Enzymology, Vol. 194, "Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270, 1991.
	Capecchi, MR. "Altering the genome by homologous recombination", Science 244:1288-1292, 1989.
✓	Cortesina G, DeStefani A, Galcazzi E. "Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low dose but not a high dose of recombinant interleukin 2 injected perilymphatically", Br J Cancer 69:572-577, 1994.



RECEIVED
RECEIVED

62		Cortesina G, DeStefani A, Giovarelli M, et al. "Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2", <i>Cancer</i> 62:2482-2485, 1988.
↓		Cregg JM, Vedvick TS, Raschke WC. "Recent Advances in the Expression of Foreign Genes in <i>Pichia pastoris</i> ", <i>BioTechnology</i> 11:905-910, 1993.
Will submit upon receipt		Culver. "Site-Directed recombination for repair of mutations in the human ADA gene", (Abstract) Antisense DNA & RNA based therapeutics, February, 1998, Coronado, CA.
62		Davies, NP., Rosewell, IR., Brüggemann, M. "Targeted alterations in yeast artificial chromosomes for interspecies gene transfer", <i>Nucleic Acids Research</i> , Vol. 20, No. 11, pp. 2693-2698, 1992.
		Deans JP., Boyd AW., Pilarski LM., Transitions from High to Low Molecular Weight Isoforms of CD45 (T200) Involve Rapid Activation of Alternate mRNA Splicing and Slow Turnover of Surface CD45R, <i>The Journal of Immunology</i> , 143:1233-1238, No. 4, August 15, 1989.
		Deans JP., Shaw J., Pearse MJ., Pilarski LM., CD45R as a Primary Signal Transducer Stimulating IL-2 and IL-2R mRNA Synthesis by CD34 ⁺ Thymocytes, <i>The Journal of Immunology</i> , 143:2425-2430, No. 8, October 15, 1989.
		Dallal, RM., Lotze, MT. The dendritic cell and human cancer vaccines, <i>Current Opinion In Immunology</i> 2000, Vol. 12, pp. 583-588.
		Dickinson, P., Kimber, WL., Kilanowski, FM., Stevenson, B.J., Porteous, DJ., Dorin, JR. "High frequency gene targeting using insertional vector", <i>Human Molecular Genetics</i> , Vol. 2, No. 8, pp. 1299-1302, 1993.
		Duff and Lincoln. "Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells", <i>Research Advances in Alzheimer's Disease and Related Disorders</i> , 1995.
		Gilboa E, Eglitis MA, Kantoff PW, Anderson WF. "Transfer and expression of cloned genes using retroviral vectors", <i>BioTechniques</i> 4(6):504-512, 1986.
Will submit upon receipt		Gillis S. et al., <i>J. Immunology</i> 120:2027-2032, 1978.
Will submit upon receipt		Hadden J. et al., <i>Immunopharmacology, JAMA</i> , 268:20:2964-2969, 1992.
62		Hadden JW. "T-Cell Adjuvants", <i>Int. J. Immunopharmac.</i> , Vol. 16, No. 9, pp. 703-710, 1994.
		Hadden JW, Endicott J, Baekkey P, Skipper P, Hadden EM. "Interleukins and contrasuppression induce immune regression of head and neck cancer", <i>Arch otolaryngol Head Neck Surg.</i> 120:395-403, 1994.
		Hadden JW, Shah AR, Sosa M, Hadden EM. "Immunotherapy with natural interleukins and/or Thymosin α , potentially augments T lymphocyte responses of hydrocortisone-treated aged mice", <i>Int'l J Immunopharmacol</i> 17:821-828, 1995.
		Hadden JW. "The immunology and immunotherapy of breast cancer: An update", <i>Int'l J Immunopharmacol</i> 21: 79-101, 1999.
		Haddden JW. "The immunopharmacology of head and neck cancer: An update", <i>Int'l J Immunopharmacol</i> 11/12:629-644, 1997.
		Hadden JW. "The treatment of zinc deficiency is an immunotherapy", <i>Int'l J Immunopharmacol</i> 17:696-701, 1995.
		Hank JA., Albertini, MR., Sondel, PM. "Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease", <i>Cancer Chemother & Biol Resp Mod</i> 18:210-222, 1999.



RECEIVED

JUN 13 2007


✓	Huston, S., Mudgett-Hunter, M., Tai, M., McCartney, J., Warren, F., Haber, E., Oppermann, H. "Protein engineering of single-chain Fv antibodies and their use in Methods in Enzymology (JJ Langone, ed.; Academic Press, New York, NY) 203:46-88, 1991.
	Huxley, C., Hagino, Y., Schlessinger, D., Olson, MV. "The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion", Genomics, 9:742-750 1991.
	Jakovovits, A., Moore, AL., Green, LL., Vergara, GJ., Maynard-Curie, CE., Austin, HA., Klapholz, S. "Germ-line transmission and expression of a human-derived yeast artificial chromosome", Nature, Vol. 362, pp. 255-261, 1993.
	Johnson, S., Bird, RE. "Construction of single-chain Fv derivations of monoclonal antibodies and their production of <i>Escherichia coli</i> ", Methods in Enzymology (JJ Langone, ed.; Academic Press New York, NY) 203:88-99, 1991.
	June CH., Ledbetter JA., Lindsten T., Thompson CB., Evidence for the Involvement of Three Distinct Signals in the Induction of IL-2 Gene Expression in Human T Lymphocytes, The Journal of Immunology, 143:153-161, No. 1, July 1, 1989.
	Kavanaugh DY., Carbone DP. "Immunologic dysfunction in cancer", Hematol-Oncol Clinics of North Amer 10(4):927-951, 1996.
	Lamb et al. "Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice", Nature Genetics, Vol. 5, pp. 22-29, 1993.
	Maass G, Schmidt W, Berger M, et al. "Priming of tumor-specific T-cells in the graining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination", Proc Nat'l Acad Sci USA, 92:5540-5542, 1995.
	Mackall, CL. "T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review", Stem Cells 2000, Vol. 18, pp10-18, 1999.
	Mackall, CL., Fleisher, TA., Brown, MR., Andrich, MP., Chen, CC., Feuerstein, MD., Horowitz, ME., McGrath, IT., Shad, AT., Steinberg, SM., Wexler, LH., Gress, RE. Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration After Intensive Chemotherapy, New England Journal of Medicine Vol. 332, pp. 143-149, 1995.
	Maclea, GD., Miles, DW., Rubens, RD., Reddish, MA., Longenecker, BM. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide", J Immunother Emphasis Tumor Immunol 19(4):309-316, 1996.
	Marshak, DR., Kadonaga, JT., Burgess, RR., Knuth, MW., Brennan, WA. Jr., Lin, S. "Strategies for Protein Purification and Characterization. A laboratory course manual", CSHL Press, 1996.
	Mastrangelo, MJ., Maguire, HC. Jr., Sato T., Nathan, FE., Berd, D. "Active specific immunization in the treatment of patients with melanoma", (Review) Seminars in Oncology 23(6):773-781, 1996.
	Meneses A, Verastrgui E, Barrera JL, Zinser J, de la Garza J, Hadden JW. "Historical findings in patients with head and neck squamos cell carcinoma receiving perilympathic natural cytokine mixture (IRX-2) prior to surgery", Arch Pathol Lab Med 122:447-454, 1998.
	Mernaugh and Mernaugh. "An overview of phage-displayed recombinant antibodies", Molecular Methods In Plant Pathology (RP Singh and US Singh, eds.; CRC Press Inc., Boca Raton, FL) pp. 359-365, 1995.
✓	Mishell, BB., Shiigi, SM. Selected Methods in Cellular Immunology, W.H. Freeman and Company, New York, 1981.



RECEIVED

JUN 12 2002

ML	Murphy GP, Tjio BA, Simmons JS, Jarisch SJ, Bowes VA, Ragde H, Rogers M., Elgamal A, Kenny, GM, Cobb, OE, Ireton, RC, Troychak M., Salgaller M., Boydston AL., "Infusion of Dendritic Cells Pulsed With HLA-A2-Specific Prostate-Specific Membrane Antigen Peptides: A Phase II Prostate Cancer Vaccine Trial Involving Patients With Hormone-Refractory Metastatic Disease," The Prostate 38:73-78, Wiley-Liss, Inc. 1999.
✓	Pearson, BE., Choi, TK. "Expression of the human β -amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice", Proc. Natl. Acad. Sci. USA, 90:10578-82, 1993.
WIR submit upon receipt	Riesenbeck et al., 1994.
WIR submit upon receipt	Rohlf I, Bröstoff J, Male D. Immunology, C.V. Mosby Co. 1989.
b ✓	Rothstein, R. "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast", Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 19, pp. 281-301, 1991.
	Saha, A., Hadden, EM., Hadden, JW. "Zinc induces thymulin secretion from human thymic epithelial cells in vitro and augments splenocytes and thymocyte response in vivo", Int'l J Immunopharmacol 17:729-734, 1995.
	Sahin, U., Tureco, O., Pfreundschuh, M. "Serological identification of human tumor antigens", Curr Opin Immunol 9:709-715, 1997.
	Sanda, MG., Smith, DC., Charles, LG., Hwang, C., Pienta, KJ., Schlom, J., Milenic, D., Panicali, D., Monte, JE. "Recombinant vaccinia-PSA (Prostvac) can include a prostate-specific immune response in androgen-modulated human prostate cancer", Urology 52:2, 1999.
	Schedl, A., Montoliu, L., Kelsey, G., Schütz, G. "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", Nature, Vol. 362, pp. 258-261, 1993.
	Sprent, J., Tough, DF. "T Cell Death and Memory", Science, Vol. 293, pp. 245-248, July 13, 2001.
	Strauss, WM., Dausman, J., Beard, C., Johnson, C. Lawrence, JB., Jaenisch, R. "Germ line transmission of a yeast artificial chromosome spanning the murine $\alpha_1(I)$ collagen locus", Science, Vol. 259, pp. 1904-1907, 1993.
	Tagawa M. "Cytokine therapy for cancer", Current Pharmaceut Design 6(6):681-699, 2000.
	Valente G, DeStefani A, Jemma C, Giovarelli M, Geuna N, Cortesina G, Forni G, Palestro G. "Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin-2. A pathologic and immunophenotypic study", Modern Pathol 3(6):702-708, 1990.
	Van der Eynde JB., Van der Brugger, P. "T cell defined tumor antigens", Curr Opin Immunol 9:684-693, 1997.
✓	Verastegui E, Barrera JL, Zinzer J, Del Rio, R., Meneses A, De La Garza, J., Hadden JW. "A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer", Int'l J Immunopharmacol 11/12:619-627, 1997.



RECEIVED

V3 ↓	Verastegui, E., Hadden, E., Barrera, J.L., Meneses, A., Hadden, J.W. 2002. natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. <i>Immunopharmacol</i> 1999 No. 12 Supplement.
✓	Wang, RF., Rosenberg, SA. "Human tumor antigens for cancer vaccine development", <i>Immunologic Reviews</i> 170:85-100, 1999.
Will submit upon receipt	Webb et al., 1973.
	Weber, J. "Tumor vaccines", <i>Medscape Anthology</i> 3:2, 2000.
W3 ↓	Whiteside, TL., Letessier, E., Hirabayashi, H., Vitolo, D., Bryant, J., Barnes, L., Snyderman, C., Johnson, JT., Myers, E., Herberman, RB., Rubin, J., Kirkwood, JM., Vlock, DR. "Evidence for Local and Systemic Activation of Immune Cells by Peritumoral injections of Interleukin 2 in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck", <i>Cancer Res.</i> 53:5654-5662, 1993.
↓	Wolf, GT., Amendola, BE., Diaz, R., Lovett, EJ., Hammerschmidt, RM., Peterson, KA. Definite vs Adjuvant Radiotherapy, <i>Arch. Otolaryngol</i> , Vol. 111:716-725, 1985.
EXAMINER CANKford	DATE CONSIDERED 4/1/4
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

PTO/SB/08 (2-92)
DEPARTMENT OF COMMERCE

Patent and Trademark Office; U.S.



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449				Docket Number (Optional) 3115.00017		Application Number 10/015,123	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Applicant John Hadden			
				Filing Date 10/26/01		Group Art Unit 1633	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)							
	Banchereau, et al. "Immunology of Dendritic Cells," Annu. Rev. Immunol. 2000, 18:767-811.						
EXAMINER 				DATE CONSIDERED 4/1/4			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

PTO/SB/08 (2-92)
DEPARTMENT OF COMMERCE

Patent and Trademark Office; U.S.

RECEIVED
JAN 31 2003
TECH CENTER 1800/2900